290 related articles for article (PubMed ID: 34909670)
21. Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases.
Abels C; Soeberdt M
Exp Dermatol; 2019 Sep; 28(9):1002-1009. PubMed ID: 31173654
[TBL] [Abstract][Full Text] [Related]
22. Psoriasis: implication to disease and therapeutic strategies, with an emphasis on drug delivery approaches.
Todke P; Shah VH
Int J Dermatol; 2018 Nov; 57(11):1387-1402. PubMed ID: 29923192
[TBL] [Abstract][Full Text] [Related]
23. Anti-Cancer Potential of Some Commonly Used Drugs.
Kumari P; Dang S
Curr Pharm Des; 2021; 27(45):4530-4538. PubMed ID: 34161206
[TBL] [Abstract][Full Text] [Related]
24. Drug repurposing in pharmaceutical industry and its impact on market access: market access implications.
Murteira S; Millier A; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226833
[TBL] [Abstract][Full Text] [Related]
25. Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation.
Thatikonda S; Pooladanda V; Sigalapalli DK; Godugu C
Cell Death Dis; 2020 Jan; 11(1):21. PubMed ID: 31924750
[TBL] [Abstract][Full Text] [Related]
26. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice.
Gao J; Chen F; Fang H; Mi J; Qi Q; Yang M
Biol Res; 2020 Oct; 53(1):48. PubMed ID: 33081840
[TBL] [Abstract][Full Text] [Related]
27. Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection.
Sahoo BM; Ravi Kumar BVV; Sruti J; Mahapatra MK; Banik BK; Borah P
Front Mol Biosci; 2021; 8():628144. PubMed ID: 33718434
[TBL] [Abstract][Full Text] [Related]
28. Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L; Jin W; Zhang J; Zhu L; Lu J; Zhen Y; Zhang L; Ouyang L; Liu B; Yu H
Acta Pharm Sin B; 2022 Feb; 12(2):532-557. PubMed ID: 35256933
[TBL] [Abstract][Full Text] [Related]
29. Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing.
Madugula SS; John L; Nagamani S; Gaur AS; Poroikov VV; Sastry GN
Comput Biol Med; 2021 Nov; 138():104856. PubMed ID: 34555571
[TBL] [Abstract][Full Text] [Related]
30. A computational multi-targeting approach for drug repositioning for psoriasis treatment.
Ibezim A; Onah E; Dim EN; Ntie-Kang F
BMC Complement Med Ther; 2021 Jul; 21(1):193. PubMed ID: 34225727
[TBL] [Abstract][Full Text] [Related]
31. Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs.
Parisi D; Adasme MF; Sveshnikova A; Bolz SN; Moreau Y; Schroeder M
Comput Struct Biotechnol J; 2020; 18():1043-1055. PubMed ID: 32419905
[TBL] [Abstract][Full Text] [Related]
32. Repurposing old drugs to fight multidrug resistant cancers.
Dinić J; Efferth T; García-Sosa AT; Grahovac J; Padrón JM; Pajeva I; Rizzolio F; Saponara S; Spengler G; Tsakovska I
Drug Resist Updat; 2020 Sep; 52():100713. PubMed ID: 32615525
[TBL] [Abstract][Full Text] [Related]
33. Emerging Pathophysiological Targets of Psoriasis for Future Therapeutic Strategies.
Yadav M; Sardana I; Sharma A; Sharma N; Nagpal K; Malik P
Infect Disord Drug Targets; 2020; 20(4):409-422. PubMed ID: 31288731
[TBL] [Abstract][Full Text] [Related]
34. Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach.
Advani D; Gupta R; Tripathi R; Sharma S; Ambasta RK; Kumar P
Neurochem Int; 2020 Nov; 140():104841. PubMed ID: 32853752
[TBL] [Abstract][Full Text] [Related]
35. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.
Ghoreschi K; Balato A; Enerbäck C; Sabat R
Lancet; 2021 Feb; 397(10275):754-766. PubMed ID: 33515492
[TBL] [Abstract][Full Text] [Related]
36. Prospects for repurposing CNS drugs for cancer treatment.
Abdelaleem M; Ezzat H; Osama M; Megahed A; Alaa W; Gaber A; Shafei A; Refaat A
Oncol Rev; 2019 Jan; 13(1):411. PubMed ID: 31044029
[TBL] [Abstract][Full Text] [Related]
37. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
Johnston TH; Lacoste AMB; Visanji NP; Lang AE; Fox SH; Brotchie JM
Neuropharmacology; 2019 Mar; 147():11-27. PubMed ID: 29907424
[TBL] [Abstract][Full Text] [Related]
38. Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.
Boyd NK; Teng C; Frei CR
Front Cell Infect Microbiol; 2021; 11():684515. PubMed ID: 34079770
[TBL] [Abstract][Full Text] [Related]
39. Revisiting Repurposing.
Sharlow ER
Assay Drug Dev Technol; 2016 Dec; 14(10):554-556. PubMed ID: 27982703
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
